A novel method for the estimation of podocyte injury: podocalyxin-positive elements in urine
Jazyk angličtina Země Česko Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
19178816
PII: file/6113/fb2008a0028.pdf
Knihovny.cz E-zdroje
- MeSH
- analýza moči metody MeSH
- časové faktory MeSH
- dospělí MeSH
- glomerulonefritida patologie terapie moč MeSH
- indukce remise MeSH
- lidé středního věku MeSH
- lidé MeSH
- podocyty patologie MeSH
- průtoková cytometrie MeSH
- senioři MeSH
- sialoglykoproteiny moč MeSH
- studie případů a kontrol MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- podocalyxin MeSH Prohlížeč
- sialoglykoproteiny MeSH
Podocytes form an outer aspect of the glomerular capillary wall and play a decisive role in its permeability for macromolecules. The main podocyte surface antigen podocalyxin, a highly electronegative sialoglycoprotein, prevents the podocyte foot processes from collapsing. Podocyte damage in glomerular disease is supposed to be accompanied by podocyte detachment, and shed podocytes and their fragments (marked by podocalyxin) may be identified in the urine. Using anti-podocalyxin monoclonal antibody, PCX+EL were counted by FACS in 38 patients with various types of active glomerulonephritis, 15 patients with chronic glomerulonephritis in long-term remission and 44 healthy controls. Urinary levels of PCX+EL were significantly higher in patients with active glomerulonephritis compared to patients with chronic glomerulonephritis in longterm remission (93 +/- 100 vs. 6.3 +/- 3.2/microl of urine, P < 0.000001) and healthy controls (4.4 +/- 2.6/microl of urine, P < 0.000001 compared to active glomerulonephritis, n.s. compared to chronic glomerulonephritis in longterm remission). These preliminary data suggest the potential of this simple method to monitor the activity of glomerular disease. Further prospective studies of larger cohorts of patients with individual glomerular diseases are clearly warranted.